Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2016)
19 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 17, 2016
Slide 1: Shareholder Presentation – Annual General Meeting
For personal use only Shareholder Presentation | Perth, WA Annual General Meeting | 17th November 2016 Global leader in applying proteomics to MedTech ASX: PIQ 1 Proteomics International Laboratories Ltd
Slide 2: Disclaimer & forward-looking statements
Disclaimer & forward-looking statements For personal use only This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 3: 2016 – a year of growth
2016 – a year of growth For personal use only Corporate – Top Ten performing IPO of 2015 (Financial Review) Analytical services – Revenue up 34% (five year average sales growing at 30%) – Major analytical contracts in biosimilars and food QC testing – WA Exporter of the Year Award; 50% export income
Slide 4: Corporate overview
Corporate overview For personal use only Capital Structure Shareholders ASX code PIQ Top 20 Shareholders 70% Shares on issue 50.6m Major Shareholders Market capitalisation (@ 29c) $14.7m Richard Lipscombe 31.9% XYLO Pty Ltd 12.4% Listed (@ 20c); raised $3m 16th April 2015 John Dunlop 7.5% 6 month pr
Slide 5: Proteins in medicine
Proteins in medicine For personal use only DNA shapes our lives. The Human Genome Project, to map human DNA, started a revolution to understand the basis of diseases beyond that of classical pathology. Determining what is happening at the molecular level can guide treatment of diseases with precisio
Slide 6: PIQ in brief
PIQ in brief For personal use only Revenue generating company – Est'd 2001 Global leader & innovator in field of proteomics World first diagnostic test at commercialisation stage World’s first company to receive ISO 17025 laboratory accreditation for proteomics services Proven technology with patent
Slide 7: Experienced board
Experienced board For personal use only Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and non-executive capacities. Companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology Ltd, Heartlink Ltd,
Slide 8: Business model
Business model For personal use only Three synergistic business areas Unifying “Promarker” platform technology - leverage & efficiency Diversified product portfolio - blue sky potential - medium term deal flow - existing cash flow 8 Proteomics International Laboratories Ltd
Slide 9: Lead diagnostic - PromarkerD
Lead diagnostic - PromarkerD For personal use only Without PromarkerD With PromarkerD 9 Proteomics International Laboratories Ltd
Slide 10: PromarkerD in brief
PromarkerD in brief For personal use only Predictive test for diagnosis of diabetic kidney disease International Diabetes Foundation estimates 415 million people globally have diabetes According to US Centre for Disease Control, 35% of adults with diabetes have chronic kidney disease; there is no ea
Slide 11: PromarkerD - routes to market
PromarkerD - routes to market For personal use only Income streams licensing fees upfront payments royalties IVD = In Vitro Diagnostic CDx = Companion Diagnostic LDT = Laboratory Developed Test Market size Country Population Diabetes cases Deal NPV Dominican Republic 11m 708,100 US$1.5m Australia 24
Slide 12: PromarkerD: status
PromarkerD: status For personal use only Stages Timing Platform technology established Publication end 2016 Clinical study – 500 patient Publication end 2016 Patent applications Granted 2016; on-going Cross-validation (antibody assay) Complete Cross-validation (LDT) Results due Nov 2016 Follow-up cl
Slide 13: Diagnostics in development
Diagnostics in development For personal use only Projects and Timelines 13 Proteomics International Laboratories Ltd
Slide 14: Asian focus – global reach
Asian focus – global reach For personal use only 14 Proteomics International Laboratories Ltd
Slide 15: Analytical services expanding
Analytical services expanding For personal use only Protein drugs can perform highly complex functions that simple chemicals cannot perform. Seven of the worlds ten best selling drugs are protein-based drugs. Fast-growing markets biosimilars & biologics QC clinical trials testing (pharmacokinetic st
Slide 16: Income growing, expenses stable
Income growing, expenses stable For personal use only IPO e lin Income Income streams ity n rtu ine analytical services grew at po dl Op n 34% in 2016 Tre 2017 on budget for 30% growth year on year new testing services commencing January 2017 Expenses deal flow from diagnostics licensing has started
Slide 17: Pending newsflow
Pending newsflow For personal use only Analytical services – Expansion into new regional markets – Growth of services and volume Diagnostic test development – Endometriosis/Mesothelioma – Pipeline expansion into other chronic diseases PromarkerD – Key Opinion Leader review – Clinical validation stud
Slide 18: Please contact
Please contact For personal use only Richard Lipscombe Managing Director T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com www.proteomicsinternational.com Terry Sweet Chairman E: t.sweet@proteomicsinternational.com Greg Wood Financial Advisor, K S Capital M:+61 416 076 377 | E: g.wood@ks
Slide 19: For personal use only
For personal use only 19 Proteomics International Laboratories Ltd
Proteomics International Laboratories — Shareholder Meeting (November 2016) on 6ix